Thursday, September 14, 2023
Pharmazz has entered into a licence agreement with Sun Pharmaceutical Industries to introduce Tyvalzi™ (Sovateltide) in India.
Under the terms of the agreement, Sun Pharma has been granted the rights to market Sovateltide in India, utilising the brand name Tyvalzi™ (Sovateltide). In return, Pharmazz will receive upfront and milestone payments, including royalties.
Tyvalzi™ is a new drug designed to address acute cerebral ischaemic stroke, a condition characterised by the interruption of blood supply to the brain, leading to potential brain damage, neurological deficits, or even death.
The mechanism of action of Tyvalzi™ involves the promotion of neurovascular remodelling, including the formation of new neurons (neurogenesis) and blood vessels (angiogenesis). Additionally, it offers protection to neural mitochondria and enhances their biogenesis.
Sovateltide (Tyvalzi™) has been approved as a new, effective, and well-tolerated therapy for treating patients with cerebral ischaemic stroke. It has shown statistically significant and clinically meaningful improvements in neurological outcomes.
Currently, there have been no new drugs approved for the treatment of stroke in over two decades, aside from rTPA. Sovateltide (Tyvalzi™), as a selective endothelin B receptor agonist, represents a groundbreaking development and can be administered up to 24 hours following a cerebral ischaemic stroke.
